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Abstract
Aims/hypothesis In contrast to microalbuminuric type 2
diabetic patients, the factors correlated with urinary albumin
excretion are less well known in normoalbuminuric patients.
This may be important because even within the normoalbu-
minuric range, higher rates of albuminuria are known to be
associated with higher renal and cardiovascular risk.
Methods At the time of screening for the Randomised
Olmesartan and Diabetes Microalbuminuria Prevention
(ROADMAP) Study, the urinary albumin/creatinine ratio
(UACR) was 0.44 mg/mmolin 4,449 type 2 diabeticpatients.
The independent correlates of UACR were analysed.
Results Independent correlates of UACR during baseline
were (in descending order): night-time systolic BP (rs=
0.19); HbA1c (rs=0.18); mean 24 h systolic BP (rs=0.16);
fasting blood glucose (rs=0.16); night-time diastolic BP
(rs=0.12); office systolic BP, sitting (rs=0.11), standing
(rs=0.10); estimated GFR (rs=0.10); heart rate, sitting (rs=
0.10); haemoglobin (rs=−0.10); triacylglycerol (rs=0.09);
and uric acid (rs=−0.08; all p≤0.001). Significantly higher
albumin excretion rates were found for the following
categorical variables: higher waist circumference (more
marked in men); presence of the metabolic syndrome;
smoking (difference more marked in males); female sex;
E. Ritz
Department of Nephrology, University of Heidelberg,
Heidelberg, Germany
G. C. Viberti
KCL Guy’s Hospital,
London, UK
L. M. Ruilope
Division of Hypertension, Hospital 12 de Octubre,
Madrid, Spain
A. J. Rabelink
Department of Nephrology and Hypertension,
Leiden University Medical Center,
Leiden, the Netherlands
J. L. Izzo Jr
Department of Medicine, Erie County Medical Center,
Buffalo, NY, USA
S. Katayama
The Fourth Department of Medicine, Saitama Medical School,
Saitama, Iruma, Japan
S. Ito
Department of Clinical Medicine, Division of Nephrology,
Endocrinology and Vascular Medicine,
Tohoku University Graduate School of Medicine,
Sendai, Japan
A. Mimran
Hospital Lapeyronie,
Montpellier, France
L. C. Rump
Medical Clinic, Marienhospital Herne,
University Clinic Ruhr-University-Bochum,
Herne, Germany
A. Januszewicz
Department of Hypertension, Institute of Cardiology,
Warsaw, Poland
J. Menne:H. Haller (*)
Department of Nephrology and Hypertension,
Hanover Medical School,
Carl-Neuberg Str. 1,
30625 Hannover, Germany
e-mail: haller.hermann@mh-hannover.de
Diabetologia (2010) 53:49–57
DOI 10.1007/s00125-009-1577-3antihypertensive treatment; use of amlodipine; insulin
treatment; family history of diabetes; and family history
of cardiovascular disease (more marked in women).
Conclusions/interpretation Although observational correla-
tions do not prove causality, in normoalbuminuric type 2
diabetic patients the albumin excretion rate is correlated with
many factors that are potentially susceptible to intervention.
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Introduction
In both diabetic and non-diabetic patients, albuminuria has
been recognisedas an important renal and cardiovascular risk
factor [1]. Although, using chemical methods, albuminuria
had been detected in patients without primary renal disease
more than 100 years ago [2], it was only after the intro-
duction of immune detection methods [3] and the recogni-
tion that albuminuria is a predictor of diabetic nephropathy
in type 1 and type 2 diabetes [4, 5] that there was an
explosive growth of information in this field.
The issue whether there is a safe threshold value of
albuminuria has recently provoked intense discussion,
mainly because in both non-diabetic [6] and diabetic [7]
patients, urinary albumin concentrations in the upper
normal range have been found to predict both cardiovascu-
lar [6] and renal plus cardiovascular events [7] in high risk
[6] and low risk [8] populations. For these and other
reasons it has been proposed by some authors to abandon
microalbuminuria as a diagnostic category and to treat
urinary albumin excretion (UAE) as a continuous variable,
much like BP or serum cholesterol concentration [9].
A great number of past and recent studies have evaluated
the evolution of UAE from normoalbuminuria to micro-
albuminuria and its correlates in adolescent [10–12] and
adult [13, 14] type 1 diabetic patients. Information on type
2 diabetic patients is scarcer and is available only for some
small cohorts [15].
The ROADMAP (Randomised Olmesartan and Diabetes
Microalbuminuria Prevention) Study [16] started in 2004
and provided a unique opportunity to investigate the factors
which correlate with albumin excretion rates across the
range of normoalbuminuric values in a large cohort of type
2 diabetic patients. Knowledge of these factors is of interest
because albuminuria is correlated with cardiovascular and
renal risk. It is the goal of the ROADMAP Study to provide
further information on the selection of strategies for
primary prevention of diabetic nephropathy.
In normoalbuminuric type 2 diabetic patients, it has
already been shown that an ACE inhibitor reduces the risk
of de novo onset of microalbuminuria [17], but, as recently
emphasised in a Cochrane review [18], there is a deficit of
information on angiotensin receptor blockers (ARBs). The
aim of the ROADMAP study is to provide evidence of
whether or not it is possible to prevent the development of
microalbuminuria by administration of the ARB olmesartan
medoxomil.
In the present study, we analysed the baseline albuminuria
levels in the ROADMAP cohort and determined which
factors correlate with the degree of albuminuria within the
so-called normoalbuminuric range.
Methods
The design of the ROADMAP Study has been described in
detail previously [16]. In the following details relating to
the baseline data will be briefly summarised.
Study design and organisation ROADMAPisarandomised,
double-blind, placebo-controlled, parallel-group, multicentre
phase 3 study that is being conducted in 262 collaborating
centres in 19 European countries. The study protocol, which
complieswiththe principlesofGoodClinicalPractice andthe
Declaration of Helsinki, has been approved by the relevant
ethics committee at each participating centre. Written
informed consent was required from each patient before
enrolment in the trial.
Study population The study has recruited 4,449 white
patients (2,054 male and 2,395 female; age range, 18–
75 years) with: type 2 diabetes (fasting plasma glucose
≥7.0 mmol/l and HbA1c ≥ 6.5%, or treatment for diabetes);
normoalbuminuria (≤35 mg [women] or ≤25 mg [men]
albumin/g urinary creatinine); and at least one additional
cardiovascular risk factor, including a lipid disorder defined
as >5.2 mmol/l cholesterol or statin treatment, HDL-
cholesterol <1.04 mmol/l, triacylglycerol >1.70 mmol/l,
high systolic BP (SBP) (≥130 mmHg) and diastolic BP
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ty (BMI≥28 m
2/kg), high waist circumference (>102 cm
[men], >88 cm [women]) or smoking more than five
cigarettes per day.
Exclusioncriteriaincludeddocumentedrenaland/orrenal–
vascular disease, estimated GFR (eGFR) <60 ml min
−1 m
−2,
recent cardiovascular event, severe hypertension (SBP>
200 mmHg and/or DBP>110 mmHg) and recent
(<26 weeks) treatment with ARBs or ACE inhibitors. Patient
recruitment commenced in 2004 and was completed in the
first half of 2006.
Office BP measurements were performed between 06:00
and 11:00 hours as trough readings and made three times in
the sitting position (with mean calculated) and once
standing, using standardised oscillometric OMRON HEM-
907 BP monitors (Omron, Stuttgart, Germany).
In 1,234 patients, 24 h ambulatory BP monitoring
(ABPM) was performed at baseline visit, using BOSO
TM-2430 ambulatory BP measurement devices (Boso,
Jungingen, Germany). BP was recorded for a 24 h period.
During the day (07:00–22:00 hours) measurements were
performed every 15 min and during the night (22:00–
07:00 hours) every 30 min.
The urinary albumin/creatinine ratio (UACR) and all
other laboratory values were determined in a central
laboratory (CRL-Medinet, Breda, the Netherlands) within
24 h after obtaining the urine and blood samples from the
patient. Urinary albumin was measured using immuno-
turbidimetry (Roche, Basel, Switzerland).
In a screening visit the potential eligibility for the study
was established by determining the UACR by morning spot
urine testing. After a pre-randomisation phase (maximum
duration 4 weeks) during which normoalbuminuria was
confirmed by two additional independent morning spot
urine tests. For the analysis of baseline values the average
of three UACR spot urine samples was used.
Statistical analysis Baseline characteristics were analysed
by the following descriptive statistics: for dichotomous and
categorical variables absolute and relative frequencies
(counts and percents) were calculated, whereby the denom-
inator for per cents is defined as the number of patients with
non-missing values.
Comprehensive data summaries were performed by
means of sample characteristics for all continuous variables
(n; missing n; arithmetic mean; SD; minimum, lower
quartile, median, upper quartile, maximum and geometric
mean if appropriate).
Correlations with albuminuria at screening were calcu-
lated for continuous variables by means of Spearman rank
correlation coefficients (univariate and multivariate analysis;
multivariate regression model with stepwise selection for
loge albumin/creatinine ratio) and for categorical variables
by means of a Wilcoxon rank sums test (two-sided test,
normal approximation of test statistics of this non-
parametric test).
eGFR ml min 11:73 m 2 
¼ 16442   PCr ðÞ
 1:154
  age in years ðÞ
 0:203  0:742 for female patients ðÞ ;
where PCr is serum creatinine measured in micromole per
litre.
Results
Patient data at baseline The baseline data are summarised
in Table 1. A total of 4,449 type 2 diabetic patients were
included in the study: 90.3% of the patients had hyperten-
Table 1 Patient data at baseline
Characteristic Total
Total 4,449
Women, n (%) 2,395 (53.8)
Age (years) 57.7±8.7 (58)
Known duration of diabetes (years) 6.1±6.0 (4.3)
Insulin treatment, n (%) 821 (18.5%)
Oral hypoglycaemic agents 3,752 (84.3)
HbA1c (%) 7.6±1.6 (7.3)
Fasting blood glucose (mmol/l) 9.1±3.1 (8.4)
SBP (mmHg) 140.8±16.3 (140.0)
DBP (mmHg) 84.0±9.8 (84.0)
BMI (kg/m
2) 31.0±4.9 (30.5)
Central obesity, n (%)
a 3,181 (71.5)
Metabolic syndrome, n (%)
b 3,528 (79.3)
Current smokers, n (%)
c 831 (18.7)
eGFR (ml min
−1 1.73 m
−2) 84.5±16.8 (83.8)
Haemoglobin (g/l) 142±13 (141)
Triacylglycerol (mmol/l) 2.1±1.3 (1.8)
Total cholesterol (mmol/l) 5.3±1.1 (5.2)
LDL-cholesterol (mmol/l) 3.2±0.9 (3.1)
HDL-cholesterol (mmol/l) 1.2±0.3 (1.2)
Uric acid (µmol/l) 321±83 (321)
Known family history of diabetes, n (%) 2,194 (49.3)
Known family history of CV events, n (%) 1,678 (37.7)
Values are means±SD (median) for continuous variables, or n (%) for
categorical variables
aHigh waist circumference: >102 cm in men, >88 cm in women
bNCEP ATP III criteria
cMore than five cigarettes per day
CV, cardiovascular
Diabetologia (2010) 53:49–57 51sion, defined as a BP>130/80 mmHg or antihypertensive
treatment; 67.5% of patients were receiving antihyperten-
sive treatment; 71.6% had lipid disorders. A high percent-
age of the patients were overweight and had central obesity.
Albuminuria at screening In these patients the albumin/
creatinine ratio in morning spot urine tests was loge
normally distributed with a median of 0.44 mg/mmol
creatinine (interquartile range 0.28–0.81; Fig. 1). In men,
the median was 0.41 mg/mmol creatinine (interquartile
range 0.24–0.75, mean 0.58±0.78, geometric mean 0.43)
and in women the median was 0.46 mg/mmol creatinine
(interquartile range 0.31–0.88, mean 0.67±0.54, geometric
mean 0.52).
The median uncorrected albumin concentration inmorning
spot urine tests in men was 4.2 mg/ml (interquartile range
2.0–7.7, mean 6.11±10.26, geometric mean 4.2) and in
women 3.2 mg/ml (interquartile range 1.5–6.2, mean 5.04±
5.27, geometric mean 3.6). The albumin/creatinine ratio is
higher in women, as expected, because of the higher UACR
exclusion values for female patients (≥3.96 mg/mmol) than
for men (≥2.83 mg/mmol); however the absolute uncorrected
albumin concentration is lower in women as a result of
markedly lower urinary creatinine concentrations in women.
Ambulatory BP (Holter monitoring) in a sub-cohort of
patients The values of 24 h ABPM prior to taking the study
medication were available in a sub-cohort of 1,234 of the
4,449 patients (567 men, 667 women). The values of
different ABPM variables are given in Table 2. The average
BP was 139.6/81.5 mmHg, confirming the results obtained
in the office BP cohort.
Correlation of albuminuria with continuous variables The
correlationsfordifferentcontinuousvariableswerecalculated.
We found a correlation with several commonly measured
variables. The strongest correlation was observed for night-
time SBP and HbA1c levels (Table 3 and Fig. 1a, b). eGFR
was correlated as well, but the correlation was moderate
(Fig. 1c). Multivariate analysis in the total cohort and in the
sub-cohort of patients with ABPM confirmed that HbA1c
and SBP had the best correlation with UACR (Tables 4
and 5).
Correlation of albuminuria with categorical variables The
correlations for a set of categorical variables were calculated.
A highlysignificantcorrelationexisted between the degreeof
UACR and variables of the metabolic syndrome, BP and
female sex (Table 6).
Night-time BP as determinant of albuminuria As the night-
time BP showed a high correlation in the uni- and
multivariate analysis (ABPM sub-cohort), the effect of BP
changes from day to night were analysed. The mean UACR
was 0.63±0.53 mg/mmol in patients with an increased BP
during the night and 0.54±0.44 mg/mmol in patients with
an inverted BP profile (i.e. increased BP during the day;
Table 7).
Discussion
This large study comprised 4,449 relatively young type 2
diabetic patients (mean age 57.7 years, range 28–75) with
an average duration of diabetes of 6.1 years. At baseline
they had moderately controlled median BP (140/84 mmHg),
but attenuated lowering of night-time SBP (−6.8%). The
median HbA1c was relatively low (7.3%), but the cardio-
vascular risk factor profile was high (67.0% had ≥4
cardiovascular risk factors).
As evaluated by Spearman correlation coefficient anal-
ysis, the factors most strongly correlated with the variation
in albuminuria within the normoalbuminuric range com-
prised BP variables, most strongly, night-time SBP and
further BP indices: mean 24 h SBP, night-time SBP, office
SBP in men (but not in women), mean 24 h DBP and office
DBP as well as pulse pressure as an index of vascular
stiffness [19].
The BP data are in good agreement with previous reports
in smaller cohorts reported in the literature. In type 1
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Fig. 1 Relationship of UACR with quintiles of night-time SBP (a), HbA1c (b) and eGFR (c)
52 Diabetologia (2010) 53:49–57diabetes, higher night-time SBP predicted the onset of
microalbuminuria [20] and the occurrence of cardiovascular
events [21], respectively. Similarly in type 2 diabetes,
attenuated dipping and elevated night-time BP are frequent
[22]. Night-time SBP was higher than daytime SBP in adult
diabetic patients who developed microalbuminuria [22].
Attenuated dipping was also found to be correlated with
coronary events [23]. In one relatively small recent study,
however, the correlation of albuminuria to night-time BP
dipping was less tight than to absolute BP [24]. Further-
more, masked hypertension is also correlated with albu-
minuria [25]. In the present study, the ABPM sub-cohort
with higher night-time than daytime BP had significantly
higher (p=0.0076 by Wilcoxon rank sum test) albumin
excretion compared with patients with lower night-time
than daytime BP.
In a very small sample of patients with type 2 diabetes, a
recent report found that pulse pressure (as a potential
indicator of vascular stiffness) was related to albumin
excretion [26]. This finding is confirmed in our much larger
cohort. The present study, in normoalbuminuric type 2
diabetic patients, extends the findings on pulse pressure in
the large cross-sectional study in microalbuminuric and
proteinuric type 2 diabetic patients by Tanaka et al. [27]:
the present study documents that a relationship between
pulse pressure and albuminuria is found even in normoal-
buminuric type 2 diabetic patients. Tanaka et al. had also
noted a correlation with aortic pulse wave velocity and
carotid intima–media thickness. In a small sample of
normo- and microalbuminuric type 2 diabetic patients,
albuminuria was correlated with markers of endothelial cell
dysfunction [28], and this may explain, at least in part, this
correlation to pulse wave velocity.
Table 2 Twenty-four hour data from ABPM
Reading Value (n=1,234)
24 h SBP 139.6±15.4 (138.9)
24 h DBP 81.5±8.1 (81.1)
Daytime SBP 143.6±15.6 (143.4)
Daytime DBP 84.3±8.5 (83.8)
Night-time SBP 133.8±17.9 (131.7)
Night-time DBP 77.4±9.4 (6.9)
24 h pulse pressure 58.1±10.3 (57.6)
Daytime pulse pressure 59.3±10.7 (59.0)
Night-time pulse pressure 56.5±11.7 (55.1)
Mean daytime SBP minus mean
night-time SBP
9.7±12.1 (10.0)
Mean daytime DBP minus mean
night-time DBP
6.9±7.3 (6.9)
Values are means±SD (median)
Table 3 Spearman rank correlation coefficients (rs) by univariate
analysis with UACR (morning spot urine) as the dependent variable
Variable rs p value
Night-time SBP
a 0.19 <0.0001
HbA1c 0.18 <0.0001
Mean 24 h SBP
a 0.16 <0.0001
Fasting glucose 0.16 <0.0001
Night-time DBP
a 0.12 <0.0001
Mean 24 h DBP* 0.11 0.0001
Office SBP (sitting) 0.11 <0.0001
Office SBP (standing) 0.10 <0.0001
eGFR 0.10 <0.0001
Haemoglobin −0.10 <0.0001
Triacylglycerols 0.09 <0.0001
Office pulse pressure (amplitude) 0.08 <0.0001
Uric acid −0.08 <0.0001
Duration of diabetes 0.07 <0.0001
Office DBP (standing) 0.07 <0.0001
Office DBP (sitting) 0.06 <0.0001
BMI 0.06 <0.0001
Total cholesterol 0.05 0.0014
No univariate Spearman correlation to: ABPM SBP variability
(maximum−minimum during 24 h period), LDL-cholesterol, HDL-
cholesterol or neutrophil counts
aABPM (Holter monitoring) data in sub-cohort of 1,234 patients
Table 4 Multivariate regression model with stepwise selection of loge
UACR
Order Variable Partial
R
2
p value Regression
coefficient
a
1 HbA1c 0.0344 <0.0001 0.05419
2 Sex (females higher) (coded
0=male, 1=female)
0.0137 <0.0001 0.16693
3 Office SBP (sitting) 0.0126 <0.0001 0.00422
4 eGFR 0.0123 <0.0001 0.00574
5 Triacylglycerols 0.0047 <0.0001 0.03430
6 Haemoglobin 0.0034 <0.0001 −0.00420
7 Family history of diabetes 0.0028 0.0002 −0.06626
8 Age 0.0023 0.0010 0.00533
9 Heart rate (sitting) 0.0020 0.0021 0.00313
10 Antihypertensive treatment 0.0021 0.0015 0.08129
11 Smoking status (ordinally
coded 0=non-smoker,
1=ex-smoker, 2=smoker)
0.0019 0.0027 0.04451
12 Fasting glucose 0.0009 0.0326 0.01034
13 HDL-cholesterol 0.0009 0.0409 −0.07907
14 Family history of CVD 0.0008 0.0436 −0.04354
aVariables with a positive sign for the regression coefficient,
increasing albuminuria; with a negative sign, decreasing albuminuria
CVD, cardiovascular disease
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correlated with indices of glycaemic control, i.e. HbA1c,
fasting glucose and duration of diabetes, as well as insulin
treatment as a categorical variable. Individuals requiring
insulin treatment and individuals with longer duration of
diabetes presumably have more advanced renal lesions.
Furthermore, BMI and the categorical variables of
elevated waist circumference and the metabolic syndrome
according to NCEP-ATP-III criteria [29] were correlated
with albuminuria as well. This observation is again in line
with previous communications and the observation that
UAE reflects insulin resistance [30].
In the general non-diabetic population [31]a n di n
essential hypertension [32] impaired glucose tolerance
increases the risk of microalbuminuria. Even sub-diabetic
glycaemia increased the risk of microalbuminuria in the
‘Framingham Offspring’ study [33]. In the UKPDS study,
the patients who presented with type 2 diabetes and had
lower glycaemia had also a lower risk of albuminuria [34].
In the Australian Diabetes, Obesity and Lifestyle Study
[35], the prevalence of albuminuria increased significantly
with increasing glycaemia. It is particularly postprandial
glycaemia, not measured in the present study, which is best
correlated with albuminuria [36], so that the overall impact
of glycaemia may even have been somewhat underesti-
mated in the present study.
In the general population the metabolic syndrome is
associated with both microalbuminuria and chronic kidney
disease [37] and the same is observed in hypertensive
patients [32].
In the general non-diabetic population, waist circumfer-
ence, an index of visceral obesity, also predicted higher
albumin excretion [38]. In type 1 [39] and type 2 diabetes
as well [40], waist circumference had been found to be a
predictor of microalbuminuria.
In the above study a positive relationship was found
between albuminuria and estimated GFR [41], indicating
that hyperfiltration presumably plays a role in the patho-
genesis of high normal albuminuria in type 2 diabetes. A
note of caution is appropriate, however, since in diabetic
Table 5 Multivariate regression model with stepwise selection of loge UACR in the sub-cohort with ABPM (n=1,234)
Order Variable Partial R
2 p value Regression coefficient
1 HbA1c 0.0484 <0.0001 0.08013
2 ABPM night-time SBP 0.0267 <0.0001 0.00405
3 Office SBP (sitting) 0.0103 0.0002 0.00484
4 Family history of diabetes 0.0094 0.0004 −0.14284
5 Antihypertensive treatment 0.0062 0.0037 0.14548
6 eGFR 0.0061 0.0039 0.00405
7 Sex (females higher) (coded 0=male, 1=female) 0.0047 0.0113 0.11502
8 Duration of type 2 diabetes 0.0042 0.0159 0.00063
9 Standing minus sitting office DBP 0.0031 0.0397 0.00768
10 Standing minus sitting office heart rate 0.0031 0.0372 −0.00815
Variable Effect on albuminuria p value
a
Increased waist circumference Higher <0.0001
Men >102 cm Higher 0.0171
Women >88 cm Higher NS
Metabolic syndrome (yes) (NCEP-ATP-III) Higher <0.0001
Female sex Higher <0.0001
Family history of diabetes Lower 0.0068
Family history of CVD Lower 0.0252
Antihypertensive medication Higher <0.0001
Amlodipine treatment Higher <0.0001
Insulin treatment Higher 0.0280
Office SBP >140 mmHg or DBP >90 mmHg Higher <0.0001
Office SBP >130 mmHg or DBP >85 mmHg Higher <0.0001
Smoking: male ex-smokers vs non-smokers and smokers Higher 0.0002
Table 6 Correlation of UACR
with categorical variables
Categorical factors that were not
significant included: family
history of renal disease, family
history of hypertension, current
use of aspirin or statins, ethnic
origin, smoking in women
aTwo-sided Wilcoxon rank sum
test; normal approximation of
test statistics
CVD, cardiovascular disease
54 Diabetologia (2010) 53:49–57patients eGFR is not a reliable indicator of true GFR, at
least in individual patients [42].
In agreement with reports in the literature on patients
with type 1 [43] and type 2 diabetes [44], albuminuria was
also correlated, although not markedly, to triacylglycerol,
total cholesterol and LDL-cholesterol.
A recent report found a positive correlation between uric
acid and albuminuria in male type 2 diabetic patients [45]
in whom confounding factors had been excluded, such as
use of allopurinol, diuretics or alcohol consumption. In the
present ROADMAP Study the correlation was negative and
this persisted even when adjusted for the potential
confounding effect of alcohol use.
The use of and presumably need for antihypertensive
medication, particularly amlodipine, was positively related to
albuminuria. The correlation with antihypertensive medica-
tion may be an example of confounding by indication, i.e.
that patients with more severe and more advanced disease
required antihypertensive medication and had also higher
rates of albuminuria. The significant effect of amlodipine,
however, may be more complex. At the time of screening the
patients had not yet received, or were off, renin–angiotensin
receptor blockers for at least 6 months.
The strength of our study is that we analysed UACR in a
largesampleoftype2diabeticpatientswithoutkidneydisease
(no microalbuminuria, eGFR>60 ml min
−1 1.73 m
−2). As the
inclusion and exclusion criteria were fulfilled by the majority
of the screened patients, this study population is represen-
tative of the majority of type 2 diabetic patients. Moreover,
our data on UACR are based on the measurement of
albuminuria in three morning spot urines.
It should be noted that only 10% of the total variance of
the UACR could be explained by the degree of blood
glucose control, BP variables, lipids and age. Verhave et al.
analysed the correlation of albumin excretion (UAE) with
cardiovascular risk factors in 7,841 patients of the PRE-
VEND cohort [45]. In their cohort, taken from the general
population, only 3.5% had diabetes and 14% microalbumi-
nuria at baseline. They found a correlation between UAE
and male sex, age, SBP, DBP, fasting glucose levels, BMI,
smoking and creatinine clearance. In a multivariate analysis
only 22% of the variance of UAE could be explained by
these variables. In the PREVEND cohort the strongest
correlation existed between glucose level and UAE. Since
all patients in the ROADMAP Study had diabetes, this
observation might explain why we were only able to explain
10% of the variance of the loge UACR. The relatively
modest correlation may also be because of the fact that most
of the patients were in the low normoalbuminuric range at
baseline. In this low range the variability is known to be
relatively high. The intra-individual variability of the three
repeated UACR measurements was 55% in the ROADMAP
cohort.
Therefore, the correlation observed points more to the
direction (thus providing a potential target of treatment)
rather than reflecting the magnitude of the relationship. The
Table 7 UACR (mg/mmol) in patients (ABPM sub-cohort) with night-time SBP lower or higher than daytime SBP
Data SBP at night ≤SBP in day (n=1,001) SBP at night ≥SBP in day (n=229) Total (n=1,230)
Mean±SD 0.54±0.44 0.63±0.53
a 0.55±0.46
Q1/median/Q3 0.26/0.37/0.68 0.31/0.45/0.82 0.27/0.42/0.68
Minimum to maximum 0.11–3.42 0.11–4.03 0.11–4.03
ap=0.0076 vs SBP at night ≤SBP in day
Q, quartile
Table 8 Determinants of baseline values for the development of
microalbuminuria
Value Study
Direct [49]
a Hope [50]
b Benedict [17]
c
Age n.d. + n.d.
Male sex + + n.d.
SBP n.d. + =
DBP n.d. = =
Pulse pressure n.d. n.d. =
BMI kg/m
2 n.d. + n.d.
Cholesterol n.d. = n.d.
Low HDL-cholesterol n.d. = n.d.
Smoking n.d. + n.d.
Baseline UAE + n.d. n.d.
Retinopathy + n.d. n.d.
HbA1c + n.d. n.d.
n.d., not determined; +, positive correlation; =, no significant
correlation
aThe Diabetes Incidence after REnal Transplantation (DIRECT)
Study: 3,326 and with type 1 and 1,905 type 2 diabetes were followed
for 4.7 years
bThe Heart Outcomes Prevention Evaluation (HOPE) Study: 9,043
patients with and without type 2 diabetes were followed for 4.5 years
and determinants of albuminuria assessed
cThe Bergamo NEphrologic Diabetes Complications Trial (BENEDICT):
1,204 patients with type 2 diabetes were followed for 3.6 years and risk
factors for the development of microalbuminuria analysed
Diabetologia (2010) 53:49–57 55identified variables correlate not only with the degree of
albuminuria within the normoalbuminuric range but might
also be predictors for the development of microalbuminuria
(Table 8).
Studies in normoalbuminuric diabetic patients have
additional limitations. First, on the one hand in diabetic
patients albuminuria is certainly correlated with the severity
of glomerular lesions [46], but the correlation is not strict,
particularly in type 2 diabetes [47]. Albuminuria therefore
does not permit conclusions with respect to diabetic
glomerular lesions. On the other hand, diabetic glomerular
lesions may even precede the onset of albuminuria [11].
Second, microalbuminuria is present in 16% of patients
at the time of diagnosis of type 2 diabetes [47]. Micro-
albuminuria frequently precedes the onset of overt type 2
diabetes [35] and one potential explanation may be the
relatively strong correlation between albuminuria and the
metabolic syndrome, a prediabetic state with insulin
resistance [48].
In conclusion, the present baseline data of the ROAD-
MAP Study suggest that albuminuria is a continuous
variable, and that even in normoalbuminuric type 2 diabetic
patients albumin excretion rates are correlated with a
number of factors which are potentially susceptible to
therapeutic intervention, although certainly correlation does
not necessarily imply causality.
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